Key factors
sym | GSK |
exch | US |
MCap | 80.75B |
Beta | 0.268 |
PE Ratio | 13.17 |
EPS | 2.98 |
Div | 0.58 |
Div Yld | 3.739 |
Div date | 2024-02-22 |
Yesterday
sym | GSK |
exch | US |
close | 40.91 |
50 Day MA | 41.91 |
200 Day MA | 37.74 |
52 Week High | 43.84 |
52 Week Low | 32.34 |
Target Price | 45.32 |
Market Cap Mln | 80755 |
Share statistics
Shares Outstanding | 2.043B |
Shares Float | 3.910B |
Percent Institutions | 14.42 |
PercentInsiders | 0.06 |
SharesShort | 4826.85K |
Short Ratio | 1.83 |
Shares Short Prior Month | 4762.02K |
Short Percent | 0.719 |
Income
Revenue TTM | 30.32B |
Revenue Per Share TTM | 14.97 |
Quarterly Revenue Growth YOY | 9.200 |
Gross Profit TTM | 19.91B |
EBITDA | 10.30B |
Diluted Eps TTM | 2.98 |
Quarterly Earnings Growth YOY | -76.5 |
earning
Operating Margin TTM | 0.203 |
PEGRatio | 1.086 |
Trailing PE | 13.17 |
EPS Estimate Current Quarter | 0.76 |
EPS Estimate Current Year | 3.96 |
EPS Estimate Next Year | 4.49 |
Earnings Share | 2.98 |
Dividend
Forward Annual Dividend Rate | 1.47 |
Forward Annual Dividend Yield | 3.739 |
Payout Ratio | 37.56 |
Dividend Date | 2024-04-11 |
Last Split Date | 2022-07-22 |
Last Split Factor | 1226:1000 |
business
Enterprise Value Ebitda | 11.08 |
Enterprise Value Revenue | 3.319 |
Book Value /share | 3.29 |
Price Book MRQ | 4.964 |
Price Sales TTM | 2.751 |
ProfitMargin | 0.162 |
ReturnOnAssetsTTM | 0.088 |
ReturnOnEquityTTM | 0.463 |
Sector
Gic Group | Pharmaceuticals, Biotechnology & Life Sciences |
Gic Industry | Pharmaceuticals |
Gic Sector | Health Care |
Gic Sub Industry | Pharmaceuticals |
Industry | Drug Manufacturers - General |
Sector | Healthcare |
Codes
ISIN | US37733W2044 |
Code | GSK |
CUSIP | 37733W105 |
CountryISO | US |
Currency Code | USD |
Currency Name | US Dollar |
Exchange | NYSE |
Currency Symbol | $ |
fund
Type | Common Stock |
UpdatedAt | 2024-04-19 |
Home Category | ADR |
info
Fiscal Year End | December |
ForwardPE | 10.31 |
Full Time Employees | 70212 |
IPODate | 1986-07-09 |
International Domestic | International Domestic |
MostRecent Quarter | 2023-12-31 |
Contact
Name | GlaxoSmithKline PLC ADR |
Address | 980 Great West Road, Brentford, United Kingdom, TW8 9GS |
Country Name | USA |
Phone | 44 20 8047 5000 |
Web URL | https://www.gsk.com |
Logo URL | /img/logos/US/GSK.png |
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.